Loading
Latest filing published 20 May 2024 for 梅花生物, €258k.
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by 常利斌 on record concern 梅花生物. Over a trading history stretching from 9 April 2024 to 20 May 2024, the count stands at 3 filings.
No open-market sale appears; the market trades are 3 purchases worth €780k. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
In size, the median ticket on the buying side is €258k. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 3 purchases show a median change of -0.7%, with the price up in 33% of them. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 20 May 2024, reports an open-market purchase of €258k in 梅花生物. The median gap between trade and publication is zero days: most filings appear on the same day. That lag is the time during which only the insider knows about the trade. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations